Microbiome therapeutics (live biotherapeutic products)

01Overview and value chain

Markers: [EC: Live Biotherapeutic Products (LBP) Regulation | OECD: bio-pharma | Regulator: FDA (USA), EMA (EU), NMPA (China)]

Live biotherapeutic products (LBPs) are a class of biological drugs containing live microorganisms — primarily bacteria, but also phages or yeasts — engineered to treat disease by modulating the composition and function of the human microbiome. Unlike dietary probiotics, LBPs undergo full clinical development and pharmaceutical licensing by the FDA, EMA and NMPA for specific indications. The sector pivoted from raw faecal microbiota transplantation (FMT) toward defined consortia: rationally assembled mixtures of pure clonal strains grown individually under GMP, eliminating donor variability and pathogen-transfer risk while holding titres of 10^10–10^11 CFU per dose.

The key directions of microbiome therapeutics are:

1. Recurrent C. difficile infection (CDI): oral spore or consortia drugs that restore gut ecology after antibiotic failure — the first two FDA-approved LBPs (Vowst, Rebyota) target this indication.
2. Inflammatory & immune disorders: defined consortia for ulcerative colitis, Crohn’s disease, irritable bowel syndrome and acute graft-versus-host disease (aGVHD).
3. Immuno-oncology modulation: live consortia that reprogram the gut to raise response rates to immune-checkpoint inhibitors in melanoma and solid tumours.
4. Gut–brain & metabolic axis: candidates addressing neurodegeneration (Alzheimer’s, ALS) and metabolic disease through the microbiome–brain signalling axis.

Sectoral value chain

[Microbiome screening & AI design] ──> [Clonal cell banking] ──> [Anaerobic fermentation]
                  │                                │                          │
        (Metagenomics, strains)        (Master cell banks)        (Bacterial biomass)
                                                                          │
[Acid-resistant encapsulation] <── [Lyophilization & stabilization] <────┘

Value chain levels

Cross-cutting technologies of the sector:

• Anoxic bioprocessing: Nitrogen/CO2/H2 gas blankets keep reactor redox below -300 mV to culture obligate anaerobes such as Faecalibacterium prausnitzii and Akkermansia muciniphila.
• AI-driven consortia design: Machine-learning models predict metabolic cross-feeding between dozens of strains to restore stable gut homeostasis.
• Colon-specific delayed release: HPMC capsules with a pH-responsive polymer coat dissolve only above pH 6.8 in the terminal ileum, shielding bacteria from gastric acid and bile.

02US

The United States leads LBP commercialization, having granted the first oral live-microbiome drug approval and hosting the deepest venture-funded pipeline.

Vowst approval, Vedanta GMP platform, donor-FMT retreat

• FDA approval of Vowst (SER-109): Seres Therapeutics’ oral Firmicutes spore fraction, co-marketed with Nestle Health Science, was FDA-approved in April 2023 for recurrent CDI prevention — the first oral LBP, opening large-scale investment into the sector.
• Vedanta Biosciences clonal platform: Vedanta shifted from donor material to fully synthetic clonal consortia, commissioning a dedicated US GMP plant that produces defined-consortium drug VE303 directly from its own Master Cell Banks.
• Regulatory retreat from donor FMT: The FDA progressively tightened oversight of stool-based FMT over standardization and pathogen-transmission risk, prioritizing molecularly characterized LBP drug forms.

03CN

China is building an integrated microbiome-therapeutics industry that couples large-scale gut-metagenome science with AI strain design and traditional-medicine co-formulation.

Gut-microbiome mapping, AI platforms, TCM integration

• Chinese Gut Microbiome Project: A CAS-led national programme has built metagenome profiles across hundreds of thousands of regional subjects, surfacing endemic protective strains as feedstock for new therapeutic lines.
• Xbiome AI platform: Shenzhen-based Xbiome uses deep learning for FMT donor matching and AI design of personalized multi-strain drugs for oncology patients (candidate XBI-302), running clinical trials in China and the US.
• TCM co-formulation: A distinctive R&D strand pairs LBPs with plant polysaccharides from traditional medicine that act as selective prebiotics to boost engraftment and activity of therapeutic strains.

04EU

The European Union is setting the global regulatory template for live biotherapeutics through European Pharmacopoeia standards and hosts a clinical leader in oncology microbiome therapy.

Ph. Eur. standards, MaaT Pharma clinical lead, PRI alignment

• European Pharmacopoeia (Ph. Eur.): EDQM issued a dedicated general chapter on live biotherapeutic products for human use, fixing common standards for purity, viability, stability and absence of antimicrobial-resistance genes across EU states.
• MaaT Pharma (France): A Lyon-based pioneer in high-diversity microbial ecosystems for oncology; lead drug MaaT013 reached pivotal phase 3 in Europe for acute graft-versus-host disease with an automated GMP plant.
• Pharmabiotic Research Institute (PRI): An EU consortium aligning academia, biotech and the EMA through scientific-advice procedures to lower regulatory barriers for microbiome drugs.

05Leading companies and research institutes

06Tech stack and innovations

The LBP manufacturing stack is built around keeping oxygen-sensitive organisms alive from cell bank to capsule.

1. Strict anaerobic cultivation (Anoxic Bioprocessing):
   • Sealed stainless bioreactors continuously sparged with high-purity N2/CO2 hold redox potential below -300 mV, keeping obligate anaerobes (Bacteroidetes, Clostridiales) viable through harvest.
2. Anaerobic lyophilization (Anaerobic Lyophilization):
   • Biomass mixed with trehalose/sucrose/antioxidant/peptide cryoprotectants is frozen to -45°C at 1°C/min and vacuum-dried, holding viability loss under 0.5 log10.
3. Colon-specific encapsulation (Delayed Release Encapsulation):
   • HPMC capsules coated with a methacrylic-acid polymer stay intact below pH 5.5 and dissolve above pH 6.8, releasing live bacteria directly in the terminal ileum.

07Value chains and production pipelines

Industrial pipeline of a defined-consortium LBP (GMP anaerobic)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. MCB vial thaw          │ ───> │ 2. Anaerobic fermentation │
│    (strict anaerobiosis)  │      │    (N2/CO2 bioreactor)    │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Strain blending &      │ <─── │ 3. TFF concentration      │
│    cryoprotectant dosing  │      │    of cell slurry         │
└───────────────────────────┘      └───────────────────────────┘
               │
               ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Lyophilization         │ ───> │ 6. Encapsulation &        │
│    (anaerobic freeze-dry) │      │    nitrogen blister fill  │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: MCB vial thaw

A working cell-bank vial of a single strain (e.g. Bacteroides thetaiotaomicron) is retrieved from liquid-nitrogen storage at -196°C; thaw and pre-culture happen inside an anaerobic laminar hood under an N2/H2 atmosphere, with purity checked by PCR and selective plating.

Stage 2: Anaerobic fermentation

The seed is transferred to a 1000–5000 L bioreactor charged with a vegan yeast-hydrolysate medium free of animal proteins; temperature holds at 37°C, pH is auto-controlled with sterile base, and the headspace is continuously sparged with a 90% N2 / 10% CO2 mix. Harvest occurs at late-exponential phase for maximum drying-stress resilience.

Stage 3: TFF concentration

The broth is cooled to 8°C to slow metabolism and fed to a tangential-flow filtration skid (0.22 µm cutoff) pre-purged with nitrogen; the slurry is concentrated 10–20x and washed with sterile saline to a titre around 10^10–10^11 CFU/ml.

Stage 4: Strain blending & cryoprotectant dosing

The wet concentrate moves to a jacketed mixer under inert gas; a sterile cryoprotectant matrix (trehalose, maltodextrin, sodium glutamate, ascorbic acid antioxidant) is dosed in, and for a multi-strain consortium the individual strain concentrates are combined in strictly controlled stoichiometric ratios per the therapeutic formulation.

Stage 5: Lyophilization

The biomass–protectant mix is spread on stainless trays under a nitrogen curtain; product is frozen to -45°C at 1°C/min, then primary drying raises temperature to -10°C to sublimate free water and secondary drying at +20°C removes bound moisture. The dry cake is milled in a sealed mill under dry nitrogen (humidity below 3%), keeping viability loss under 0.5 log10.

Stage 6: Encapsulation & nitrogen blister fill

The lyophilized powder is blended with magnesium stearate and silicon dioxide excipients and dosed into enteric HPMC capsules on an automatic filler under inert gas; capsules are blister-packed in barrier Alu-Alu foil with each cell nitrogen-flushed. Each batch is released only after anaerobic-plate viable counts (CFU/capsule), 16S rRNA strain-ratio confirmation, LAL endotoxin testing and acid-disintegration checks.